| Literature DB >> 29379746 |
Chika Sumiyoshi1, Manbu Takaki2, Yuko Okahisa2, Thomas L Patterson3, Philip D Harvey4, Tomiki Sumiyoshi5.
Abstract
The UCSD Performance-based Skills Assessment Brief (the UPSA-B) has been widely used for evaluating functional capacity in patients with schizophrenia. The utility of the battery in a wide range of cultural contexts has been of concern among developers. The current study investigated the validity of the Japanese version of the UPSA-B as a measure of functional capacity and as a co-primary for neurocognion. Sixty-four Japanese patients with schizophrenia and 83 healthy adults entered the study. The Japanese version of the UPSA-B (UPSA-B Japanese version) and the MATRICS Cognitive Consensus Battery Japanese version (MCCB Japanese version) were administered. Normal controls performed significantly better than patients, with large effect sizes for the Total and the subscale scores of the UPSA-B. Receiver Operating Characteristic (ROC) curve analysis revealed that the optimal cut-off point for the UPSA-B Total score was estimated at around 80. The UPSA-B Total score was significantly correlated with the MCCB Composite score and several domain scores, indicating the relationship between this co-primary measure and overall cognitive functioning in Japanese patients with schizophrenia. The results obtained here suggest that the UPSA-B Japanese version is an effective tool for evaluating disturbances of daily-living skills linked to cognitive functioning in schizophrenia, providing an identifiable cut-off point and relationships to neurocognition. Further research is warranted to evaluate the psychometrical properties and response to treatment of the Japanese version of the UPSA-B.Entities:
Keywords: Co-primary measure; Functional capacity; MATRICS Cognitive Consensus Battery (MCCB); Neurocognition; Receiver Operating Characteristic (ROC) curve analysis
Year: 2014 PMID: 29379746 PMCID: PMC5779073 DOI: 10.1016/j.scog.2014.08.002
Source DB: PubMed Journal: Schizophr Res Cogn ISSN: 2215-0013
The UPSA-B studies in the US and other countries.
| Country | Study | Participants | N | UPSA-B | Sample | ||
|---|---|---|---|---|---|---|---|
| Total | Finances | Communication | |||||
| US | SCZ | 161 | 69.9 | – | – | Patients with schizophrenia or schizoaffective disorder who were community living with Ashkenazi Jewish backgrounds. Results were obtained from the analyses of subsamples | |
| BD | 130 | 88.5 | |||||
| SCZ | 162 | 73.0 | – | – | Recruited at the Validation of Intermediate Measure (VIM) study under the MATRICS initiative | ||
| SCZ | 3445 | 74.0 | – | – | Enrolled in the genomic study based on a Veterans Administration initiative (CSP#572) | ||
| BD | 4624 | 83.0 | |||||
| SCZ | 323 | 70.0 | – | – | Participants were in a large multi-site trial assessing the comparative effects of antipsychotic treatment with lurasidone or risperidone | ||
| SCZ | 194 | 72.2 | – | – | Older patients with schizophrenia enrolled in longitudinal study of the course of cognitive and functional status. They were recruited at Mt. Sinai School of Medicine or other hospitals | ||
| SCZ (Mt. Sinai) | 238 | 68.7 | – | – | Part of data was from | ||
| SCZ (UCSD) | 116 | 56.5 | Recruited from Board and Care facilities in San Diego who enrolled in Functional Adaptation Skills Training | ||||
| NC | 109 | 84.5 | Healthy subjects recruited at a naturally occurring retirement community (NORC) in Manhattan | ||||
| Independent living SCZ | 99 | 72.5 | – | – | Recruited at the UCSD Advanced Center for Interventions and Services Research. A subset of participants was part of the Functional Adaption Skills Training (FAST) study ( | ||
| Non-independent living SCZ | 335 | 54.5 | |||||
| Assisted-living, SCZ, Schizoaffective | 163 | 53.9 | – | – | Part of data was from the FAST study | ||
| Community-living SCZ, Schizoaffective | 73 | 54.7 | |||||
| China | SCZ (Chinese) | 272 | 37.6 | – | – | Inpatients treated at a municipal psychiatric hospital in Beijing | |
| BD (Chinese) | 61 | 55.2 | |||||
| Major depression (Chinese) | 50 | 47.9 | |||||
| NC (Chinese) | 284 | 64.3 | |||||
| India | SCZ (Indian) | 160 | 67.6 | – | – | Recruited from 6 different sites recommended by the MATRICS Scientific Advisory Board | |
| US | SCZ (Atlanta Skyland Trail) | 55 | 75.5 | Enrolled in the Validation of Everyday Real-World Outcomes (VALERO) study ( | |||
| SCZ (Atlanta VA Medical Center) | 40 | 81.7 | 40.1 | – | |||
| SCZ (UCSD Outpatients Psychiatric Services) | 100 | 75.3 | |||||
| SCZ, Schizoaffective | 183 | 40.0 | 36.4 | Data from the three different services referred in the VALERO study ( | |||
| SCZ, Schizoaffective | 236 | 68.8 | – | – | Schizophrenia or schizoaffective participants in a longitudinal study of cognitive and functional status. Outpatients recruited from several sites in New York and its suburbs | ||
| SCZ | 244 | 37.4 | 31.5 | Data from the same general data set in | |||
| SCZ | 116 | 75.6 | 39.5 | 36.1 | Data from the same resource in | ||
| BD | 89 | 88.7 | 45.7 | 43.0 | |||
| SCZ | 367 | 77.5 | 41.1 | 36.4 | |||
| Sweden | SCZ (Swedish) | 146 | 68.9 | 38.7 | 30.9 | Outpatients recruited at a country council-founded clinic at NU Health Care Hospital | |
| SCZ, Schizoaffective, Delusional (Swedish) | 211 | 69.4 | 38.8 | 30.6 | Participants were in the study of Clinical Long-term Investigation of Psychosis in Sweden (CLIPS) | ||
| Denmark | First episode SCZ (Danish) | 117 | 77.5 | 40.2 | 37.3 | Participants were in the multi-site randomized clinical trial for cognitive remediation program (the NEUROCOM trial) | |
SCZ: schizophrenia, BD: bipolar disorder, NC: normal controls.
MAX score: Total = 100, Finances = 50, Communication = 50.
Patients were mostly outpatients except for McIntosh et al., 2011.
A base line score.
Characteristics of participants.
| NC | SCZ | Effect size | t/F (df) | p | Interpretations | |
|---|---|---|---|---|---|---|
| N (M/F) | 83 (71/12) | 64 (34/30) | – | |||
| Age | 34.6 (9.4) | 35.2 (11.2) | – | t = − 0.13 (143) | 0.72 | NC = SCZ |
| Education | 16.6 (1.1) | 13.6 (2.4) | – | t = 10.12 (143) | < 0.000 | NC > SCZ |
| Duration | – | 9.7 (8.1) | – | – | ||
| Drug (mg) | – | 444.8 (492.0) | – | – | ||
| BPRS_Positive | – | 10.0 (5.9) | – | – | ||
| BPRS_Negative | – | 7.5 (3.4) | – | – | ||
| BPRS_Total | – | 36.5 (12.8) | – | – | ||
| MCCB Composite | 510.5 (47.3) | 376.3 (76.0) | 2.1 | F = 67.30 (1,140) | < 0.000 | NC > SCZ |
| UPSA-B Total | 82.1 (8.6) | 69.5 (13.7) | 1.1 | t = 6.80 (145) | < 0.000 | NC > SCZ |
| Finances | 48.7 (3.3) | 43.8 (7.8) | 0.8 | F = 46.24 (1,145) | < 0.000 | NC > SCZ |
| Communication | 33.4 (7.6) | 25.7 (9.5) | 0.9 |
NC: normal controls, SCZ: patients with schizophrenia.
Cohen's d for normal controls vs. patients.
Mean (SD).
CPZ equivalent.
Fig. 1ROC curves for UPSA-B Total score.
Fig. 2UPSA-B profiles for normal controls (A) and patients with schizophrenia (B). Task 13: Speaking to the phone a name and an address given by a tester. Task 16: Leaving a voice-mail message to a reschedule of an appointment. Task 19: Remembering preparations designated by a medical appointment.
Correlations between the MCCB and the UPSA-B.
| MCCB domains and tests | NC | SCZ |
|---|---|---|
| Overall composite | 0.27 | 0.35 |
| Speed of Processing Composite | 0.15 | 0.25 |
| Trail Making Test | ||
| BACS Symbol Coding | ||
| Fluency | ||
| Working Memory Composite | 0.21 | 0.36 |
| WMS-II Spatial Span | ||
| Letter Number Sequencing | ||
| Verbal Learning | 0.06 | 0.36 |
| HVLT-R | ||
| Reasoning and Problem solving | − 0.01 | 0.20 |
| NAB Maze | ||
| Visual Learning | 0.19 | 0.24 |
| BVMT-R | ||
| Social Cognition | 0.16 | − 0.10 |
| MSCEIT Managing Emotion | ||
| Attention/Vigilance | 0.23 | 0.27 |
| CPT-IP |
NC: normal controls, SCZ: patients with schizophrenia.
p < 0.05.
p < 0.01.
The sum of the T scores for seven domains.
The sum of TMT, BACS SC, and Fluency.
The sum of WMS III SS and LNS.